Role of Fibroblasts in Cancer

成纤维细胞在癌症中的作用

基本信息

  • 批准号:
    7941541
  • 负责人:
  • 金额:
    $ 19.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-30 至 2011-09-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Tumors are known as wounds that do not heal - implying that cells involved in angiogenesis and injury response, such as endothelial cells and fibroblasts, have a prominent role in the progression, growth and spread of cancers. Our knowledge regarding the role of the resting and the activated fibroblasts (also known as carcinoma-associated fibroblasts, CAF) in cancer is still evolving. Fibroblast production of growth factors, chemokines and extracellular matrix likely facilitates the angiogenic recruitment of endothelial cells and pericytes. Moreover, the precise role of fibroblasts in the recruitment and the formation of metastasis is completely unknown. Therefore, this grant application is focused on the role of fibroblast in cancer progression, with specific emphasis on metastasis. Emerging data from other laboratories and our own preliminary data suggest that fibroblasts are a heterogeneous population. In the tumor microenvironment, we have now identified a population of CAF that are positive for fibroblast specific protein-1 (FSP1) but not for alpha-smooth muscle actin (aSMA). Our studies demonstrate for the first time that not all CAF are aSMA+. Additionally, specific ablation of FSP1+/alphaSMA- fibroblasts using transgenic mice, which harbor FSP1 promoter driven thymidine kinase protein (FSP1-tk), demonstrate that FSP1+ fibroblasts are critical for the formation of metastasis without a significant impact on the growth of angiogenic primary tumors. Furthermore, we demonstrate that VEGF, SDF-1 and Tenascin-C, might mediate the formation of metastatic nodules. To further evaluate the role of these fibroblasts in the formation of metastasis, we propose the following aims in this proposal: 1. To evaluate the contribution of FSP1+ fibroblasts in the growth of primary tumors and recruitment of metastasis, 2. To address the contribution of VEGF produced by FSP1+ fibroblasts in the growth of primary tumors and the formation of metastasis, 3. To investigate the contribution of SDF-1, produced by FSP1+ fibroblasts, a downstream effector of VEGF, in the formation of metastasis, and 4. To study the contribution of Tenascin-C, a FSP1+ fibroblast-produced extracellular matrix protein, in the organization of metastasis nodules. Successful completion of experiments proposed in this grant application will provide crucial insights into the role of FSP1+ fibroblasts as key determinants for the organization of metastasis. PUBLIC HEARLTH RELEVANCE: Cancer cells are not the only constituent cells within a primary tumor and secondary metastasis. Other cells including fibroblasts are found inside the primary tumor and secondary metastatic nodules. The role of such fibroblasts in cancer progression and metastasis is unknown. This proposal addresses the role of fibroblasts in facilitating metastasis.
描述(由申请人提供):肿瘤被称为不愈合的伤口-这意味着参与血管生成和损伤反应的细胞,如内皮细胞和成纤维细胞,在癌症的进展、生长和扩散中具有突出作用。 我们对静止和活化的成纤维细胞(也称为癌相关成纤维细胞,CAF)在癌症中的作用的认识仍在不断发展。 成纤维细胞产生生长因子、趋化因子和细胞外基质可能促进内皮细胞和周细胞的血管生成募集。 此外,成纤维细胞在募集和转移形成中的确切作用完全未知。 因此,这项拨款申请的重点是成纤维细胞在癌症进展中的作用,特别强调转移。 来自其他实验室的新数据和我们自己的初步数据表明,成纤维细胞是一个异质性群体。 在肿瘤微环境中,我们现在已经鉴定出对成纤维细胞特异性蛋白-1(FSP 1)呈阳性但对α-平滑肌肌动蛋白(aSMA)不呈阳性的CAF群体。 我们的研究首次证明并非所有CAF都是aSMA+。 此外,使用携带FSP 1启动子驱动的胸苷激酶蛋白(FSP 1-tk)的转基因小鼠特异性消融FSP 1 +/α SMA-成纤维细胞,证明FSP 1+成纤维细胞对于转移的形成至关重要,而对血管生成原发性肿瘤的生长无显著影响。 此外,我们证明VEGF、SDF-1和Tenascin-C可能介导转移结节的形成。 为了进一步评估这些成纤维细胞在转移形成中的作用,我们提出了以下目标:1。为了评估FSP 1+成纤维细胞在原发肿瘤生长和转移招募中的作用,2.为了阐明FSP 1+成纤维细胞产生的VEGF在原发性肿瘤生长和转移形成中的作用,3.研究由FSP 1+成纤维细胞产生的SDF-1(VEGF的下游效应物)在转移形成中的作用。研究Tenascin-C(一种FSP 1+成纤维细胞产生的细胞外基质蛋白)在转移结节组织化中的作用。 成功完成本资助申请中提出的实验将为FSP 1+成纤维细胞作为转移组织的关键决定因素的作用提供重要见解。 公共卫生相关性:癌细胞不是原发性肿瘤和继发性转移瘤中的唯一组成细胞。 在原发性肿瘤和继发性转移结节内发现其他细胞,包括成纤维细胞。 这种成纤维细胞在癌症进展和转移中的作用尚不清楚。 该提议解决了成纤维细胞在促进转移中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RAGHU KALLURI其他文献

RAGHU KALLURI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RAGHU KALLURI', 18)}}的其他基金

Biology and Function of Exosomes in Cancer
外泌体在癌症中的生物学和功能
  • 批准号:
    10680453
  • 财政年份:
    2022
  • 资助金额:
    $ 19.46万
  • 项目类别:
Mechanisms associated with organotropic metastasis
与器官转移相关的机制
  • 批准号:
    10439900
  • 财政年份:
    2021
  • 资助金额:
    $ 19.46万
  • 项目类别:
Mechanisms associated with organotropic metastasis
与器官转移相关的机制
  • 批准号:
    10295926
  • 财政年份:
    2021
  • 资助金额:
    $ 19.46万
  • 项目类别:
Mechanisms associated with organotropic metastasis
与器官转移相关的机制
  • 批准号:
    10532826
  • 财政年份:
    2021
  • 资助金额:
    $ 19.46万
  • 项目类别:
Exosomes in Cancer Therapy
外泌体在癌症治疗中的应用
  • 批准号:
    9897907
  • 财政年份:
    2016
  • 资助金额:
    $ 19.46万
  • 项目类别:
Exosomes in Cancer Therapy
外泌体在癌症治疗中的应用
  • 批准号:
    10058770
  • 财政年份:
    2016
  • 资助金额:
    $ 19.46万
  • 项目类别:
Exosomes in Cancer Therapy
外泌体在癌症治疗中的应用
  • 批准号:
    9230198
  • 财政年份:
    2016
  • 资助金额:
    $ 19.46万
  • 项目类别:
Employing mouse models to translate early detection of pancreas cancer
利用小鼠模型转化胰腺癌的早期检测
  • 批准号:
    8904197
  • 财政年份:
    2015
  • 资助金额:
    $ 19.46万
  • 项目类别:
Employing mouse models to translate early detection of pancreas cancer
利用小鼠模型转化胰腺癌的早期检测
  • 批准号:
    9097660
  • 财政年份:
    2015
  • 资助金额:
    $ 19.46万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8555539
  • 财政年份:
    2011
  • 资助金额:
    $ 19.46万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 19.46万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.46万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 19.46万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.46万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 19.46万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 19.46万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.46万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 19.46万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 19.46万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.46万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了